Search Blog
November 2013
« Oct   Dec »

Tags Announces Market Mover Reports on JCP, HPTO, SKTO, and IDIX


By Stock Publisher

Whether you are bull or bear, TrendingWallStreet has got you covered. Take a few minutes to register with us at to get exclusive access to all of our free stock reports.

J. C. Penney Company, Inc. (NYSE: JCP) shares closed up 8.53 percent on nearly 60 million shares traded this past Friday. The stock traded in between $7.57 and 8.32 a share that day. Shares for the company rose as much as 10.8 percent on Friday after Wall Street firm ITG Investment Research lifted its sales forecast for J. C. Penney, citing “improving sales trends” in five of the last seven weeks.

Get more information on J. C. Penney Company, Inc. and free access to the in-depth equity report at:

HopTo Inc. (OTCBB: HPTO) was one of the most actively traded stocks on the OTCBB market this Friday. The stock closed modestly in the red down 0.24 percent. The Company announced on Thursday that their comprehensive mobile workspace app has been submitted for the required authorization to distribute through the Apple App Store.  Pending certification, hopTo anticipates an early November debut on the iPad.

Get more information on HopTo Inc. and free access to the in-depth equity report at:

SK3 Group Inc. (OTC: SKTO) shares closed down 27.74 percent on Friday and saw a significant outbreak in trading volume. The stock traded nearly 30 million shares. The Company announced that it has completed its preliminary consolidated financial statements for the quarter ended September 30, 2013. The financial reports are now being reviewed by its outside financial and legal advisors for inclusion in the quarterly report to OTC Markets, due by November 15, 2013. 

Get more information on SK3 Group Inc. and free access to the in-depth equity report at:

Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) shares closed up 40.27 percent on Friday and traded in between 3.25 and 4.74 a share. The stock traded about 9.1 million shares. The stock soared as much as 44% after the Company reported its third-quarter results and providing an update on its pipeline. For the quarter, Idenix reported just $19,000 in revenue compared to $32.3 million in the year-ago period while reporting a net loss of $34 million, or $0.25 per share, compared to a profit of $4.3 million, or $0.03, last year.

Get more information on Idenix Pharmaceuticals Inc. and free access to the in-depth equity report at:


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.